Cargando…

Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

OBJECTIVE: To assess the effects of exenatide on body weight and glucose tolerance in nondiabetic obese subjects with normal or impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). RESEARCH DESIGN AND METHODS: Obese subjects (n = 152; age 46 ± 12 years, female 82%, weight 108.6 ± 23.0...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenstock, Julio, Klaff, Leslie J., Schwartz, Sherwyn, Northrup, Justin, Holcombe, John H., Wilhelm, Kenneth, Trautmann, Michael
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2010
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875418/ https://www.ncbi.nlm.nih.gov/pubmed/20332357 http://dx.doi.org/10.2337/dc09-1203

Ejemplares similares

Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
por: Wysham, Carol H., et al.
Publicado: (2017)

Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes
por: Henry, Robert R., et al.
Publicado: (2013)

Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study
por: Wysham, Carol H, et al.
Publicado: (2020)

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes
por: Koska, Juraj, et al.
Publicado: (2010)

Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study
por: Berg, J K, et al.
Publicado: (2011)

Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial
por: Kothare, Prajakti A, et al.
Publicado: (2012)

Exenatide improves glucocorticoid-induced glucose intolerance in mice
por: Zhao, Ruiying, et al.
Publicado: (2011)

Predictors of deterioration of glucose tolerance and effects of lifestyle intervention aimed at reducing visceral fat in normal glucose tolerance subjects with abdominal obesity
por: Akita, Etsuko F, et al.
Publicado: (2010)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes: The T-emerge 2 trial
por: Rosenstock, Julio, et al.
Publicado: (2013)

DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
por: Buse, John B., et al.
Publicado: (2010)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials
por: Vetter, Marion L., et al.
Publicado: (2019)

Population pharmacokinetics of exenatide
por: Cirincione, Brenda, et al.
Publicado: (2016)

Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years
por: Taylor, Kristin, et al.
Publicado: (2011)

Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?
por: Boughton, Charlotte K., et al.
Publicado: (2020)

Exenatide Sensitizes Insulin-Mediated Whole-Body Glucose Disposal and Promotes Uptake of Exogenous Glucose by the Liver
por: Zheng, Dan, et al.
Publicado: (2009)

Switching to Once-Daily Liraglutide From Twice-Daily Exenatide Further Improves Glycemic Control in Patients With Type 2 Diabetes Using Oral Agents
por: Buse, John B., et al.
Publicado: (2010)

Exenatide once weekly for the treatment of type 2 diabetes: effectiveness and tolerability in patient subpopulations
por: Pencek, R, et al.
Publicado: (2012)

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QT(c) interval in healthy subjects
por: Darpö, Börje, et al.
Publicado: (2013)

The Performance and Usability of a Factory-Calibrated Flash Glucose Monitoring System
por: Bailey, Timothy, et al.
Publicado: (2015)

Plasma glucose and insulin response to two oral nutrition supplements in adults with type 2 diabetes mellitus
por: Huhmann, Maureen B, et al.
Publicado: (2016)

Exenatide Improves Glucose Homeostasis and Prolongs Survival in a Murine Model of Dilated Cardiomyopathy
por: Vyas, Arpita Kalla, et al.
Publicado: (2011)

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness
por: Taylor, Simeon I., et al.
Publicado: (2023)

Long-acting preparations of exenatide
por: Cai, Yunpeng, et al.
Publicado: (2013)

Adipokine Pattern in Subjects with Impaired Fasting Glucose and Impaired Glucose Tolerance in Comparison to Normal Glucose Tolerance and Diabetes
por: Tönjes, Anke, et al.
Publicado: (2010)

Glucose challenge increases circulating progenitor cells in Asian Indian male subjects with normal glucose tolerance which is compromised in subjects with pre-diabetes: A pilot study
por: Nathan, Abel A, et al.
Publicado: (2011)

Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance
por: Shannon, Chris, et al.
Publicado: (2018)

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)
por: Rosenstock, Julio, et al.
Publicado: (2013)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study
por: Christiansen, Mark P., et al.
Publicado: (2019)

Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance
por: Schmoelzer, Isabella, et al.
Publicado: (2006)

Exenatide Treatment Alone Improves β-Cell Function in a Canine Model of Pre-Diabetes
por: Ionut, Viorica, et al.
Publicado: (2016)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Effect of renal impairment on the pharmacokinetics of exenatide
por: Linnebjerg, Helle, et al.
Publicado: (2007)

Evolution of Exenatide as a Diabetes Therapeutic
por: Bhavsar, Sunil, et al.
Publicado: (2013)

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes
por: Song, Sun Ok, et al.
Publicado: (2013)

A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes
por: Genovese, Stefano, et al.
Publicado: (2017)

Model‐Based Evaluation of Exenatide Effects on the QT Interval in Healthy Subjects Following Continuous IV Infusion
por: Cirincione, Brenda, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7m02lck9ug3bgtudpd3n3ret6e